Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.

University of North Carolina (UNC)

Status: Terminated

Conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02833714

14-2877

Details and patient eligibility

About

The purpose of this research is to characterize the effect of teriflunomide on the activation of B-cells, as well as its capacity to modify B-cell cytokine secretion. The in-vitro identified effects of teriflunomide on the expression of B-cell activation markers, costimulatory and antigen presenting molecules, as well as on cytokine secretion, will then be confirmed in a cohort of Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with this medication.

Enrollment: 26 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• confirmed diagnosis of RRMS according to McDonald's diagnostic criteria,
• age 18-55,
• an extended disability status score (EDSS) of 1.5-5.5.

Exclusion criteria

• Previous treatment with DMT.